RayKnowChina Research Map
Shortlist

RecruitingLung cancerBreast cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

Integrin αvβ6-targeted PET in Malignant Tumors

An open trial on lung cancer and breast cancer, registered on ClinicalTrials.gov. Led by Zhongnan Hospital of Wuhan University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05835570, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 85 years; sex: all

    Registered eligibility fields

  2. Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer;

    Inclusion criterion 1

  3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;

    Inclusion criterion 4

  4. Participation in another clinical trial within 30 days prior to PET/CT scan;

    Exclusion criterion 5

  5. Female subjects of reproductive age, male subjects and their partners agree to use reliable contraceptive measures (e.g., abstinence, birth control pills, injectable contraceptives, or subcutaneous contraceptive implants) until 6 months after the completion of the study;

    Inclusion criterion 5

    Pregnant or breastfeeding women;

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05835570, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer;
  • Age ≥18 years, regardless of gender;
  • No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET/CT;
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;
  • Female subjects of reproductive age, male subjects and their partners agree to use reliable contraceptive measures (e.g., abstinence, birth control pills, injectable contraceptives, or subcutaneous contraceptive implants) until 6 months after the completion of the study;
  • Participants should voluntarily consent to the clinical trial, and have the ability to understand and sign an informed consent form.

Exclusion Criteria:

  • Known allergy to injection or its excipients;
  • Severe liver or renal dysfunction;
  • Claustrophobia or other psychiatric disorders;
  • History of other malignant tumors;
  • Participation in another clinical trial within 30 days prior to PET/CT scan;
  • Pregnant or breastfeeding women;
  • Refusal to participate or request for withdrawing from the clinical study;
  • Other conditions deemed unsuitable for inclusion by investigator.

Quoted from ClinicalTrials.gov, NCT05835570, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05835570, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05835570